Cryptophycin payloads are powerful blockers of cell division. Antibody-linked versions are being investigated to improve how these drugs reach tumors.
Cryptophycin-55 derivatives have been attached to trastuzumab and tested in HER2-positive cell lines and mouse xenografts. Cryptophycin-52 is a tubulin inhibitor; the primary conjugate study investigated release and conversion of the cryptophycin-55 prodrug. This is an experimental tubulin-directed scaffold. Activity of the free molecule, prodrug and intact antibody conjugate must be distinguished.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/